Longevity Leaders Logo White

RNA_Leaders_Logo_White



SCIENTIFIC, CLINICAL AND COMMERCIAL DEVELOPMENT OF RNA THERAPEUTICS AND VACCINES


16-17 March 2022
Congress Center Basel
Switzerland



#rnaleaders
@lsxleaders

DOWNLOAD BROCHURE

Created by    LSX

A new paradigm for disease prevention



RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.

With that in mind, we can’t wait to bring the community together, face-to-face, for the first annual RNA Leaders World Congress.

So, if you’re passionate about all things RNA do join us, and more than 150 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders World Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.

RNA Leaders World Congress


Gold partner



Axolabs


Meet our speakers



Douglas Fambrough, CEO, Dicerna Pharmaceuticals

Douglas Fambrough

CEO
Dicerna Pharmaceuticals
Bob Brown, CSO, Dicerna Pharmaceuticals

Bob Brown

CSO
Dicerna Pharmaceuticals
Brett Monia, CEO, Ionis Pharmaceuticals

Brett Monia

CEO
Ionis Pharmaceuticals
Sylke Poehling, Senior Vice President and Global Head, Therapeutic Modalities, Roche

Sylke Poehling

Senior Vice President and Global Head
Therapeutic ModalitiesRoche
Shalini Andersson, Chief Scientist, New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

Shalini Andersson

Chief Scientist, New Therapeutic Modalities & Head of Oligonucleotide Discovery
AstraZeneca
Denis Drygin, CSO, Regulus Therapeutics

Denis Drygin

CSO
Regulus Therapeutics
Gene Liau, CSO, Stoke Therapeutics

Gene Liau

CSO
Stoke Therapeutics
Kathleen McCarthy, Co-Founder & Chief Scientific Officer, Skyhawk Therapeutics

Kathleen McCarthy

Co-Founder & Chief Scientific Officer
Skyhawk Therapeutics
Laura Sepp-Lorenzino, CSO, Intellia Therapeutics

Laura Sepp-Lorenzino

CSO
Intellia Therapeutics
Aimee Jackson, CSO, Atalanta Therapeutics

Aimee Jackson

CSO
Atalanta Therapeutics
Nagy Habib, Founder and Head of R&D, MiNA Therapeutics

Nagy Habib

Founder and Head of R&D
MiNA Therapeutics
Sudha Chivukula, Head of RNA Technology, Research & External Innovation, Sanofi Pasteur

Sudha Chivukula

Head of RNA Technology, Research & External Innovation
Sanofi Pasteur
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly

Tim Luker

VP, S&E – Emerging Technology & Innovation, Corporate Business Development
Eli Lilly
Alexandra Bause, Co-Founder, Investment Director & Head of VentureLabs, Apollo Health Ventures

Alexandra Bause

Co-Founder, Investment Director & Head of VentureLabs
Apollo Health Ventures
Marie Wikstrom Lindholm, SVP and Head of Molecular Design, Silence Therapeutics

Marie Wikstrom Lindholm

SVP and Head of Molecular Design
Silence Therapeutics
Matthew Disney, Professor, Department of Chemistry, Scripps Research

Matthew Disney

Professor, Department of Chemistry
Scripps Research

SEE ALL SPEAKERS

“We still have work to do, but the future is bright for RNA therapies.”
Lorna Harries, CSO, Senisca

What will you learn?



  • How the RNA field has accelerated in the past two years, including major scientific and clinical developments
  • New advancements in systemic and topical delivery platforms and their applications
  • How computational biology is advancing RNA drug discovery including new tools for target, mechanism and molecule discovery
  • Latest pre-clinical updates spanning mRNA, RNAi, antisense and targeting RNA with small molecules
  • Application of gene therapy and RNA editing approaches

DOWNLOAD BROCHURE

500+ companies actively developing RNA therapeutics

4000+ live clinical trials for RNA therapeutics and vaccines

2 major mRNA vaccine approvals in 2020

3 RNAi therapeutic approvals in the past 4 years

1500+ investors actively looking to fund RNA technology

96 successful fund raises by mid 2021 (vs 101 total in 2020)

More than $1.65bn raised by RNA biotech mid 2021

Millions of lives saved by mRNA vaccines to date

Become a partner



Do you offer products or services to support RNA drug development? The pharma and biotech executives attending RNA Leaders World Congress want to meet you! They are looking for:

  • Delivery platforms
  • Contract research
  • Equipment supply
  • Target discovery tools
  • CDMO and CMC
  • Reagent providers
  • RNA editing tools
  • RNA analysis
  • Legal services

SPONSORSHIP PROSPECTUS

Female Founders

Networking, Dialogue And Mentorship For Women In Health And Life Sciences
Members save 25% off all LSX events.

FIND OUT MORE

Subscribe to hear speaker announcements, ticket offers and more